Catalogue

Background
The antibody to HBsAG is used for the detection of this antigen in liver cells, which are infected by hepatitis B virus. In healthy liver and other tissues staining is negative. Hepatitis B Virus is a widely distributed Virus, which is known as the main cause of liver cirrhosis. A long-term consequence of hepatitis B infection could be the development of liver carcinoma. Especially medical personal is affected by hepatitis B (due to inappropriate handling of virus contaminated material!) HBsAg subtypes ad and ay.

Source

Immunogen: Purified Hepatitis B surface antigen

Product
Antibody solution in stabilizing phosphate buffer pH 7.3. Contains 0.09 % sodium azide**. The volume is sufficient for at least 100 immunohistochemical tests (100 µl working solution / test). Use appropriate antibody diluent e.g. BIOLOGO Art .No. PU002.

Purification Method: Antibody solution in stabilizing phosphate buffer pH 7.3. Contains 0.09 % sodium azide**. The volume is sufficient for at least 100 immunohistochemical tests (100 µl working solution / test). Use appropriate antibody diluent e.g. BIOLOGO Art .No. PU002.

Secondary Reagents: We recommend the use of BIOLOGO's Universal Staining System DAB (Art. No. DA005) or AEC (Art.-No. AE005).

Specificity

Species Reactivity: Hepatitis B Virus

Applications
IHC(P)

Incubation Time: 60 min at RT

Working Concentration: (liquid conc.) 1:10 - 1:25

Pre-Treatment: No protease pre-treatment required! Blocking of endogenous peroxidase with 1% peroxide in methanol!

Positive Control: HBV-infected liver

Storage
2-8°C

Caution
This product is intended FOR RESEARCH USE ONLY, and FOR TESTS IN VITRO, not for use in diagnostic or therapeutic procedures involving humans or animals. It may contain hazardous ingredients. Please refer to the Safety Data Sheets (SDS) for additional information and proper handling procedures. Dispose product remainders according to local regulations.This datasheet is as accurate as reasonably achievable, but Exalpha Biologicals accepts no liability for any inaccuracies or omissions in this information.

References
1. Beasley R.P., et al. (1981) Hepatocellular carcinoma and hepatitis B virus: a prospective study of 22,707 men in Taiwan. Lancet ii; 1129 2. Hoofnagel J.H., and Alter H.J. (1984) Chronic viral hepatitis. In: Vyas G.N. et al. Eds. Viral hepatitis and liver disease. Grune & Stratton, N.Y. pp 97 ff. 3. Swensen P.D. et al. (1988). Antigenic analysis of HBsAg with monoclonal antibodies specific for S protein and pre-S2. Viral hepatitis and liver disease. Alan R. Liess, Inc. pp. 627ff.

Safety Datasheet(s) for this product: